From ABCD to E for endothelin in resistant hypertension.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36603580.
- Also identified by DOI 10.1016/j.cell.2022.12.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The potent vasoconstrictor peptide endothelin-1 has long been recognized as a physiological regulator of vascular tone. However, pharmacological blockade of the endothelin-1 pathway has few proven indications thus far. A recent clinical trial for resistant hypertension published in The Lancet may yet herald a new era for endothelin receptor antagonists into the clinical mainstream.
Medical subject headings
- Endothelin-1
- Hypertension